CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing TOL2, a novel therapy aimed at curing myasthenia gravis, a severe autoimmune neuromuscular disorder. Unlike existing treatments that only alleviate symptoms, TOL2 seeks to induce long-term remission, potentially transforming the lives of affected patients and addressing a significant…
Myasthenia gravis (MG) is a rare disease affecting 2/10.000 people.
Although being a rare disease, MG is the most common chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. MG restricts patients from having a full participation in everyday activities, frequently leading to unemployment and reducing their quality of life.
Many patients may eventually experience a myast…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
